Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Apogee Therapeutics, Inc.NASDAQ: APGE
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q2 FY2026 stock-based compensation of $16.66M rose 46.9% year over year, behind the +60.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 2.9% from the prior quarter. Over 3 fiscal years it compounded at +178.5% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +46.9% toward the trailing-twelve-month pace of +60.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 46.28M USD
- Year-over-year change
- +98.3%
- 3-year CAGR
- +178.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.28M | +98.3% |
| FY2024 | 2024-12-31 | 23.33M | +282.3% |
| FY2023 | 2023-12-31 | 6.1M | +184.9% |
| FY2022 | 2022-12-31 | 2.14M | — |
Stock-Based Compensation vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +60.4% is the 3rd highest of 10, against a peer median of +1.1%.
- Over three fiscal years its annual growth of +178.5% compares with a peer median of +22.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.83M USD | -11.3% | +5.5% | 21.3% | |
| LTM Sep 2026 | $64.29M USD | +20.9% | +38.1% | — | |
| LTM Jun 2026 | $58.29M USD | -12.7% | +2.3% | 13.0% | |
| LTM Jun 2026 | $57.63M USD | +60.4% | +178.5% | — | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $50.54M USD | +76.5% | +154.3% | — |
| LTM Sep 2026 | $36.45M USD | +48.9% | +240.5% | 591.2% | |
| LTM Mar 2026 | $33.64M USD | +1.1% | +7.4% | — | |
| LTM Jun 2026 | $28.46M USD | +203.0% | +66.4% | — | |
AAPGAscentage Pharma Group International | FY2025 | CN¥20.87M CNY | -0.2% | -1.9% | 3.7% |
| LTM Sep 2026 | $7.7M USD | -87.8% | — | 0.6% | |
| Peer median (excluding APGE) | — | +1.1% | +22.8% | 13.0% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (39.79M) | (83.99M) | (182.15M) | (255.84M) |
| Depreciation & Amortization | 0 | 0 | 189K | 1.42M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.14M | 6.1M | 23.33M | 46.28M |
| Change in Working Capital | 9.82M | 6.11M | (2M) | (15.48M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 418K | 1.61M | (1.07M) | 150K |
| Other Working Capital | 9.4M | 4.49M | (930K) | (15.63M) |
| Other Non-Cash Items | 11.4M | (2.98M) | (10.55M) | (3.82M) |
| Operating Cash Flow | (16.43M) | (74.76M) | (171.17M) | (227.45M) |
| Capital Expenditures | 0 | (167K) | (1.15M) | (5.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (303.74M) | (649.45M) | (642.3M) |
| Sales of Investments | 0 | 30M | 350.14M | 467.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (273.91M) | (300.46M) | (179.57M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 168.32M | 315.39M | 493.48M | 396.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1.63M | 0 |
| Financing Cash Flow | 168.32M | 315.39M | 495.11M | 396.49M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 151.89M | (33.28M) | 23.47M | (10.53M) |
| Free Cash Flow | (16.43M) | (74.93M) | (172.33M) | (232.6M) |
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.